<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160064</url>
  </required_header>
  <id_info>
    <org_study_id>ADCT-402-N01</org_study_id>
    <nct_id>NCT05160064</nct_id>
  </id_info>
  <brief_title>Long-term Registry of Patients Treated With Loncastuximab Tesirine</brief_title>
  <official_title>Long-term Longitudinal Cohort Registry of Patients Treated With Loncastuximab Tesirine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ADC Therapeutics S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ADC Therapeutics S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective and prospective multi-center observational study of patients with B-cell&#xD;
      lymphomas treated with loncastuximab tesirine treatment in real-world practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess treatment patterns and generate evidence on the&#xD;
      effectiveness and safety of loncastuximab tesirine treatment in real-world practice. This&#xD;
      clinical trial information was submitted voluntarily under the applicable law and, therefore,&#xD;
      certain submission deadlines may not apply. (That is, clinical trial information for this&#xD;
      applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health&#xD;
      Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections&#xD;
      402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>48 Months</target_duration>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 48 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 48 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Up to 48 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 48 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Partial Response (PR)</measure>
    <time_frame>Up to 48 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Complete Response (CR)</measure>
    <time_frame>Up to 48 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>Up to 48 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients with Adverse Events</measure>
    <time_frame>Up to 48 Months</time_frame>
    <description>Includes serious adverse events (SAEs) and adverse events (AEs) Grade 3 or higher for the events of: edema, myelosuppression, infections, and cutaneous reactions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalizations</measure>
    <time_frame>Up to 48 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalizations</measure>
    <time_frame>Up to 48 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for Hospitalizations</measure>
    <time_frame>Up to 48 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Surgeries</measure>
    <time_frame>Up to 48 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of Surgeries</measure>
    <time_frame>Up to 48 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for Surgeries</measure>
    <time_frame>Up to 48 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Emergency Room Visits</measure>
    <time_frame>Up to 48 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for Emergency Room Visits</measure>
    <time_frame>Up to 48 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Outpatient Visits</measure>
    <time_frame>Up to 48 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for Outpatient Visits</measure>
    <time_frame>Up to 48 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>B-Cell Lymphomas</condition>
  <arm_group>
    <arm_group_label>Patients Treated with Loncastuximab Tesirine</arm_group_label>
    <description>Patients with B-cell lymphomas and other diagnoses who have been treated with loncastuximab tesirine will have their medical chart data entered into the registry.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients initiated or initiating commercially available loncastuximab tesirine treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be â‰¥ 18 years of age at the time of consent.&#xD;
&#xD;
          -  Initiated or initiating commercially available loncastuximab tesirine treatment.&#xD;
&#xD;
          -  Written informed consent must be obtained prior to any registry activities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior loncastuximab tesirine exposure in clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Contact ADC Therapeutics</last_name>
    <phone>954-903-7994</phone>
    <email>clinical.trials@adctherapeutics.com</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 3, 2021</study_first_submitted>
  <study_first_submitted_qc>December 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Loncastuximab tesirine</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>Relapsed/Refractory Diffuse Large B-Cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

